Company / Shareholders' Equity
Sonoma Pharmaceuticals, Inc. Shareholders' Equity History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$6.1M
FY2025
5-year range
$5.4M / $8.7M
FY2021-FY2025
Trend
-23.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 9 years, ranging from $5M in FY2022 to $21M in FY2018.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of -10.2%.
Declined from $9M to $6M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +4.6%
- 5-Year CAGR
- -10.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -10.2%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 23.1% year-over-year.
- Peak shareholders' equity was recorded in FY2018.
- Lowest shareholders' equity in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | - | - |
| FY2025 | $6.1M | -23.1% |
| FY2024 | $8.0M | -8.3% |
| FY2023 | $8.7M | +62.2% |
| FY2022 | $5.4M | -4.6% |
| FY2021 | $5.6M | -46.4% |
| FY2020 | $10.5M | -31.6% |
| FY2019 | $15.3M | -28.5% |
| FY2018 | $21.4M | +111.4% |
| FY2017 | $10.1M | -15.9% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026